eMedicine Specialties > Gastroenterology > Stomach

Gastritis, Chronic

Author: Sandeep Mukherjee, MB, BCh, MPH, FRCPC, Associate Professor, Department of Internal Medicine, Section of Gastroenterology and Hepatology, University of Nebraska Medical Center; Consulting Staff, Section of Gastroenterology and Hepatology, Veteran Affairs Medical Center
Coauthor(s): Antonia R Sepulveda, MD, PhD, Associate Professor of Pathology, University of Pennsylvania School of Medicine; Director of Surgical Pathology, Director of Surgical Pathology Fellowship, Department of Pathology and Laboratory Medicine, Hospital of the University of Pennsylvania; Maria P Dore, MD, Associate Professor, Department of Medicine, Institute of Internal Medicine, University of Sassari, Italy; Franco Bazzoli, MD, Professor, Department of Internal Medicine and Gastroenterology, University of Bologna, Italy
Contributor Information and Disclosures

Updated: Aug 24, 2009

Introduction

Background

Chronic gastritis is a histopathologic entity characterized by chronic inflammation of the stomach mucosa. Gastritides can be classified based on the underlying etiologic agent (eg, Helicobacter pylori, bile reflux, nonsteroidal anti-inflammatory drugs [NSAIDs], autoimmunity, allergic response) and the histopathologic pattern, which may suggest the etiologic agent and clinical course (eg, H pylori –associated multifocal atrophic gastritis). The image below depicts chronic active gastritis caused by H pylori.

Helicobacter pylori-caused chronic active gastrit...

Helicobacter pylori-caused chronic active gastritis. Genta stain (20X). Multiple organisms (brown) are visibly adherent to gastric surface epithelial cells.

Helicobacter pylori-caused chronic active gastrit...

Helicobacter pylori-caused chronic active gastritis. Genta stain (20X). Multiple organisms (brown) are visibly adherent to gastric surface epithelial cells.


Other classifications are based on the endoscopic appearance of the gastric mucosa (eg, varioliform gastritis). Although minimal inflammation is observed in some gastropathies, such as those associated with NSAID intake, these entities are discussed in this article because they are frequently included in the differential diagnosis of chronic gastritis.

Chemical or reactive gastritis is caused by injury of the gastric mucosa by reflux of bile and pancreatic secretions into the stomach, but it can also be caused by exogenous substances, including NSAIDs, acetylsalicylic acid, chemotherapeutic agents, and alcohol.1 These chemicals cause epithelial damage, erosions, and ulcers that are followed by regenerative hyperplasia detectable as foveolar hyperplasia, and damage to capillaries, with mucosal edema, hemorrhage, and increased smooth muscle in the lamina propria.

Inflammation in these lesions caused by chemicals is minimal or lacking; therefore, the term gastropathy or chemical gastropathy is more appropriate to describe these lesions than is the term chemical or reactive gastritis as proposed by the updated Sydney classification of gastritis.2 Importantly, mixed forms of gastropathy and other types of gastritis, especially H pylori gastritis, may coexist.

No single classification of gastritis provides an entirely satisfactory description of all types of gastritis.3 However, an etiologic classification provides a direct target toward which therapy can be directed, and, for this reason, the etiologic classification is used in this article. In many instances, chronic gastritis is a relatively minor manifestation of diseases that predominantly manifest in other organs or manifest systemically, such as gastritis in individuals who are immunosuppressed.

Helicobacter gastritis is a primary infection of the stomach and is the most frequent cause of chronic gastritis. Cases of histologically documented chronic gastritis are diagnosed as chronic gastritis of undetermined etiology or gastritis of undetermined type when none of the findings reflect any of the described patterns of gastritis and a specific cause cannot be identified.

Pathophysiology

The pathophysiology of chronic gastritis complicating a systemic disease, such as hepatic cirrhosis, uremia, or another infection, is described in the relevant disease articles. The pathogenesis of the most common forms of gastritis is described as follows.

H pylori- associated chronic gastritis

H pylori are gram-negative rods that have the ability to colonize and infect the stomach. The bacteria survive within the mucous layer that covers the gastric surface epithelium and the upper portions of the gastric foveolae. The infection is usually acquired during childhood. Once the organism has been acquired, has passed through the mucous layer, and has become established at the luminal surface of the stomach, an intense inflammatory response of the underlying tissue develops.4

The presence of H pylori is associated with tissue damage and the histologic finding of both an active and chronic gastritis. The host response to H pylori and bacterial products is composed of T- and B-cell lymphocytes, denoting chronic gastritis, followed by infiltration of the lamina propria and gastric epithelium by polymorphonuclear leukocytes that eventually phagocytize the bacteria. The presence of polymorphonuclear leukocytes in the gastric mucosa is diagnostic of active gastritis.

The interaction of H pylori with the surface mucosa results in the release of proinflammatory cytokine interleukin (IL)-8, which leads to recruitment of polymorphonuclear cells and may begin the entire inflammatory process. Gastric epithelial cells express class II molecules, which may increase the inflammatory response by presenting H pylori antigens, leading to further cytokine release and more inflammation. High levels of cytokines, particularly tumor necrosis factor-a (TNF-α)5 and multiple interleukins (eg, IL-6, IL-8, IL-10), are detected in the gastric mucosa of patients with H pylori gastritis.

Leukotriene levels are also quite elevated, especially leukotriene B4, which is synthesized by host neutrophils and is cytotoxic to gastric epithelium. This inflammatory response leads to functional changes in the stomach, depending on the areas of the stomach involved. When inflammation affects the gastric corpus, parietal cells are inhibited, leading to reduced acid secretion. Continued inflammation results in loss of parietal cells, and the reduction in acid secretion becomes permanent.

Antral inflammation alters the interplay between gastrin and somatostatin secretion, affecting G cells (gastrin-secreting cells) and D cells (somatostatin-secreting cells), respectively. Specifically, gastrin secretion is abnormal in individuals who are infected with H pylori, with an exaggerated meal-stimulated release of gastrin being the most prominent abnormality. When the infection is cured, neutrophil infiltration of the tissue quickly resolves, with slower resolution of the chronic inflammatory cells. Paralleling the slow resolution of the monocytic infiltrates, meal-stimulated gastrin secretion returns to normal.

Differences in virulence factors that characterize different strains of H pylori influence the clinical outcome of H pylori infection. People infected with H pylori strains that secrete the vacuolating toxin A (vacA) are more likely to develop peptic ulcers than people infected with strains that do not secrete this toxin. Another set of virulence factors is encoded by the H pylori pathogenicity island (PAI). The PAI contains the sequence for several genes and encodes the CAGA gene. Strains that produce CagA protein (CagA+) are associated with a greater risk of development of gastric carcinoma and peptic ulcers. However, infection with CagA- strains also predisposes the person to these diseases.6,7,8

H pylori- associated chronic gastritis progresses with the following 2 main topographic patterns that have different clinical consequences:

  • Antral predominant gastritis is characterized by inflammation and is mostly limited to the antrum. Individuals with peptic ulcers usually demonstrate this pattern of gastritis.
  • Multifocal atrophic gastritis is characterized by involvement of the corpus and gastric antrum with progressive development of gastric atrophy (loss of the gastric glands) and partial replacement of gastric glands by an intestinal-type epithelium (intestinal metaplasia). Individuals who develop gastric carcinoma and gastric ulcers usually demonstrate this pattern of gastritis.

Most of the people who are infected with H pylori do not develop significant clinical complications, and they remain carriers with asymptomatic chronic gastritis. Some individuals who carry additional risk factors may develop peptic ulcers, gastric mucosa–associated lymphoid tissue (MALT) lymphomas, or gastric adenocarcinomas.

An increased duodenal acid load may precipitate and wash out bile salts, which normally inhibit the growth of H pylori. Progressive damage to the duodenum promotes gastric foveolar metaplasia, resulting in sites for H pylori growth and more inflammation. This cycle results in the increasing inability of the duodenal bulb to neutralize acid entering from the stomach until changes in duodenal bulb structure and function are sufficient for an ulcer to develop. H pylori can survive in areas of gastric metaplasia in the duodenum, contributing to the development of peptic ulcers.

MALT lymphomas may develop in association with chronic gastritis secondary to H pylori infection. The healthy stomach lacks organized lymphoid tissue, but, following infection with H pylori, lymphoid tissue is universally present. Acquisition of gastric lymphoid tissue is thought to be due to persistent antigen stimulation from byproducts of chronic infection with H pylori. The continuous presence of H pylori results in the persistence of MALT in the gastric mucosa, which eventually may progress to form low- and high-grade MALT lymphomas. MALT lymphomas are monoclonal proliferations of neoplastic B cells that have the ability to infiltrate gastric glands. Gastric MALT lymphomas typically are low-grade T-cell–dependent B-cell lymphomas, and the antigenic stimulus of gastric MALT lymphomas is thought to be H pylori.

Another complication of H pylori gastritis is the development of gastric carcinomas, especially in individuals who develop extensive atrophy and intestinal metaplasia of the gastric mucosa. Although the relationship between H pylori and gastritis is constant, only a small proportion of individuals infected with H pylori develop gastric cancer. The incidence of gastric cancer usually parallels the incidence of H pylori infection in countries with a high incidence of gastric cancer and is consistent with H pylori being the cause of the precursor lesion, chronic atrophic gastritis.

Persistence of the organisms and associated inflammation during long-standing infection is likely to permit the accumulation of mutations in the gastric epithelial cells' genome, leading to an increased risk of malignant transformation and progression to adenocarcinoma. Studies have provided evidence of the accumulation of mutations in the gastric epithelium secondary to oxidative DNA damage associated with chronic inflammatory byproducts and secondary to deficiency of DNA repair induced by chronic bacterial infection.

Although the role of H pylori in peptic ulcer disease is well established, the clinical role of the infection in nonulcer dyspepsia remains very controversial. H pylori eradication may be beneficial for symptom relief in a small proportion of patients, but routine H pylori testing and treatment in nonulcer dyspepsia is not currently widely accepted. Therefore, consider H pylori eradication strategies in patients with nonulcer dyspepsia on an individual patient-by-patient basis.

Infectious granulomatous gastritis

Granulomatous gastritis (see image below) is a rare entity. Tuberculosis may affect the stomach and cause caseating granulomas. Fungi can also cause caseating granulomas and necrosis, a finding that is usually observed in patients who are immunosuppressed.

Granulomatous chronic gastritis. Noncaseating gra...

Granulomatous chronic gastritis. Noncaseating granulomas in the lamina propria. Courtesy of Sydney Finkelstein, MD, PhD, University of Pittsburgh.

Granulomatous chronic gastritis. Noncaseating gra...

Granulomatous chronic gastritis. Noncaseating granulomas in the lamina propria. Courtesy of Sydney Finkelstein, MD, PhD, University of Pittsburgh.


Gastritis in patients who are immunosuppressed

Cytomegalovirus (CMV) infection of the stomach is observed in patients with underlying immunosuppression. Histologically, typical intranuclear eosinophilic inclusions and, occasionally, smaller intracytoplasmic inclusions are found (see image below).

Chronic gastritis. Typical cytomegalovirus inclus...

Chronic gastritis. Typical cytomegalovirus inclusions in lamina propria capillary endothelial cells. Courtesy of Sydney Finkelstein, MD, PhD, University of Pittsburgh.

Chronic gastritis. Typical cytomegalovirus inclus...

Chronic gastritis. Typical cytomegalovirus inclusions in lamina propria capillary endothelial cells. Courtesy of Sydney Finkelstein, MD, PhD, University of Pittsburgh.


A patchy, mild inflammatory infiltrate is observed in the lamina propria. Viral inclusions are present in gastric epithelial cells and in endothelial or mesenchymal cells in the lamina propria. Severe necrosis may result in ulceration. Herpes simplex causes basophilic intranuclear inclusions in epithelial cells. Mycobacterial infections by Mycobacterium avium-intracellulare are characterized by diffuse infiltration of the lamina propria by histiocytes, which rarely form granulomas (see image below).

Chronic gastritis. Mycobacterium avium-intracellu...

Chronic gastritis. Mycobacterium avium-intracellulare in gastric lamina propria macrophages. Courtesy of Sydney Finkelstein, MD, PhD, University of Pittsburgh.

Chronic gastritis. Mycobacterium avium-intracellu...

Chronic gastritis. Mycobacterium avium-intracellulare in gastric lamina propria macrophages. Courtesy of Sydney Finkelstein, MD, PhD, University of Pittsburgh.


Autoimmune gastritis

This type of gastritis is associated with serum antiparietal and anti-intrinsic factor (IF) antibodies. The gastric corpus undergoes progressive atrophy, IF deficiency occurs, and patients may develop pernicious anemia.

The development of chronic atrophic gastritis limited to corpus-fundus mucosa and marked diffuse atrophy of parietal and chief cells characterize autoimmune atrophic gastritis. Autoimmune gastritis is associated with serum antiparietal and anti-IF antibodies that cause IF deficiency, which, in turn, causes decreased availability of cobalamin and, eventually, pernicious anemia in some patients.

Autoantibodies are directed against at least 3 antigens, including IF, cytoplasmic (microsomal-canalicular), and plasma membrane antigens. Two types of IF antibodies are detected (ie, types I and II). Type I IF antibodies block the IF-cobalamin binding site, thus preventing the uptake of vitamin B-12. Cell-mediated immunity also contributes to the disease. T-cell lymphocytes infiltrate the gastric mucosa and contribute to epithelial cell destruction and resulting gastric atrophy. A recent study reported that gender, age, vitamin B12, folate, renal function, atrophic gastritis and the methylenetetrahydrofolate (MTHF) 677TT genotype were significant determinants of homocysteine levels, which were positively related to incident cardiovascular diseases.9

Chronic reactive chemical gastropathy

This type of gastritis is associated with long-term intake of aspirin or NSAIDs. It also develops when bile-containing intestinal contents reflux into the stomach. Although bile reflux may occur in the intact stomach, most of the features associated with bile reflux are typically found in patients with partial gastrectomy, in whom the lesions develop near the surgical stoma. The mechanisms through which bile alters the gastric epithelium involve the effect of several bile constituents. Both lysolecithin and bile acids can disrupt the gastric mucous barrier, allowing the back diffusion of positive hydrogen ions and resulting in cellular injury. Pancreatic juice enhances epithelial injury in addition to bile acids. In contrast to other chronic gastropathies, minimal inflammation of the gastric mucosa typically occurs in chemical gastropathy.

Chronic noninfectious granulomatous gastritis

Noninfectious diseases are the usual cause of gastric granulomas and include Crohn disease, sarcoidosis, and isolated granulomatous gastritis. Crohn disease demonstrates gastric involvement in approximately 33% of the cases. Granulomas have also been described in association with gastric malignancies, including carcinoma and malignant lymphoma. Sarcoidlike granulomas may be observed in people who use cocaine, and foreign material is occasionally observed in the granuloma.

Lymphocytic gastritis

This is a type of chronic gastritis with dense infiltration of the surface and foveolar epithelium by T lymphocytes and associated chronic infiltrates in the lamina propria. Because of similar histopathology relative to celiac disease, lymphocytic gastritis has been proposed to result from intraluminal antigens. High anti-H pylori antibody titers have been found in patients with lymphocytic gastritis, and, in limited studies, the inflammation disappeared after H pylori eradication. However, many patients with lymphocytic gastritis are serologically negative for H pylori. A number of cases may develop secondary to intolerance to gluten and drugs such as ticlopidine.

Eosinophilic gastritis

Large numbers of eosinophils may be observed with parasitic infections such as those caused by Eustoma rotundatum and anisakiasis. Eosinophilic gastritis can be part of the spectrum of eosinophilic gastroenteritis. Although the gastric antrum is commonly affected and can cause gastric outlet obstruction, this condition can affect any segment of the GI tract and can be segmental.10 Patients frequently have peripheral blood eosinophilia. In some cases, especially in children, eosinophilic gastroenteritis can result from food allergy, usually to milk or soy protein. Eosinophilic gastroenteritis can also be found in some patients with connective tissue disorders, including scleroderma, polymyositis, and dermatomyositis.

Radiation gastritis

Small doses of radiation (up to 1500 R) cause reversible mucosal damage, whereas higher radiation doses cause irreversible damage with atrophy and ischemic-related ulceration. Reversible changes consist of degenerative changes in epithelial cells and nonspecific chronic inflammatory infiltrate in the lamina propria. Higher amounts of radiation cause permanent mucosal damage, with atrophy of fundic glands, mucosal erosions, and capillary hemorrhage. Associated submucosal endarteritis results in mucosal ischemia and secondary ulcer development.

Ischemic gastritis

Ischemic gastritis is believed to result from atherosclerotic thrombi arising from the celiac and superior mesenteric arteries.

Frequency

United States

Approximately 35% of adults are infected with H pylori, but the prevalence of infection in minority groups and immigrants from developing countries is much higher. Children aged 2-8 years in developing nations acquire the infection at a rate of about 10% per year; whereas, in the United States, children become infected at a rate of less than 1% per year. This major difference in the rate of acquisition in childhood is responsible for the differences in epidemiology between developed countries and developing countries. Socioeconomic differences are the most important predictor of the prevalence of the infection in any group. Higher standards of living are associated with higher levels of education and better sanitation, thus the prevalence of infection is lower.

In the United States and in other countries with modern sanitation and clean water supplies, the rate of acquisition has been decreasing since 1950. The rate of infection in people with several generations of their families living at a high socioeconomic status is in the range of 10% to 15%. This is probably the lowest the prevalence can decline spontaneously until eradication or vaccination programs are instituted.

Lymphocytic gastritis has been estimated to represent approximately 1.4% of all gastritides. The disease has been reported in various parts of the world but more commonly in Europe, and it appears to be less common in the United States.

Chronic reactive chemical gastropathy is one of the most common and poorly recognized lesions of the stomach.

International

An estimated 50% of the world population is infected with H pylori; therefore, chronic gastritis is extremely frequent. H pylori infection is highly prevalent in Asia and in developing countries, and multifocal atrophic gastritis and gastric adenocarcinomas are more prevalent in these areas.11

Autoimmune gastritis is a relatively rare disease, most frequently observed in individuals of northern European descent1,12 and blacks. The prevalence of pernicious anemia, resulting from autoimmune gastritis, has been estimated at 127 cases per 100,000 members of the population in the United Kingdom, Denmark, and Sweden. The frequency of pernicious anemia is increased in patients with other immunologic diseases, including Graves disease, myxedema, thyroiditis, and hypoparathyroidism.

Mortality/Morbidity

Morbidity of chronic gastritis is strongly related to the underlying cause. Chronic gastritis as a primary disease, such as H pylori- associated chronic gastritis, may progress as an asymptomatic disease in some patients, whereas other patients may report dyspeptic symptoms.

  • The clinical course may be worsened when patients develop any of the possible complications of H pylori infection such as peptic ulcer or gastric malignancy.
  • H pylori gastritis is the most frequent cause of MALT lymphoma. Patients with chronic atrophic gastritis may have a 12- to 16-fold increased risk of developing gastric carcinoma, compared with the general population. Approximately 1 in 6 infected persons develop peptic ulcer, and, in the United States, approximately 25% develop hypochlorhydria or achlorhydria. The lifetime risk of gastric cancer is in the range of 1% to 3%.
  • Environmental factors, such as diet and standard of living, are important in determining which pathway is prevalent in a country or area.
  • In patients with autoimmune gastritis, the major effects are consequent to the loss of parietal and chief cells and include achlorhydria, hypergastrinemia, loss of pepsin and pepsinogen, anemia, and an increased risk of gastric neoplasms. Autoimmune gastritis represents the most frequent cause of pernicious anemia in temperate climates. The risk of gastric adenocarcinoma appears to be at least 2.9 times higher in patients with pernicious anemia than in the general population.

Race

H pylori -associated chronic gastritis appears to be more common among Asian and Hispanic people than in people of other races.

  • In the United States, H pylori infection is more common among black, Native American, and Hispanic people than among white people, a difference that has been attributed to socioeconomic factors.
  • Autoimmune gastritis is more frequent in individuals of northern European descent and in black people, and it is less frequent in southern European and Asian people.
  • Sarcoidosis is more frequent in young black people, whereas isolated granulomatous gastritis is more common in older white people.

Sex

  • Chronic H pylori- associated gastritis affects both sexes with similar frequency.
  • The female-to-male ratio for autoimmune gastritis has been reported to be 3:1.
  • Lymphocytic gastritis affects men and women at similar rates.

Age

Age is the most important variable relating to the prevalence of H pylori infection, with persons born before 1950 having a notably higher rate of infection than people born after 1950. For example, roughly one half of people older than 60 years are infected, compared with 20% of people younger than 40 years. This increase in infection prevalence with age is largely apparent rather than real, reflecting a continuing overall decline in the prevalence of H pylori infection.
 
Because the infection is typically acquired in childhood and is lifelong, the high proportion of older individuals (eg, 60 y or older) who are infected is the long-term result of infection that occurred in childhood when standards of living were lower. The prevalence will decrease as people who are currently aged 40 years and have a lower rate of infection grow older (a birth cohort phenomenon).

  • H pylori gastritis is usually acquired during childhood, and complications typically develop later.
  • Patients with autoimmune gastritis usually present with pernicious anemia, which is typically diagnosed in individuals aged approximately 60 years. However, pernicious anemia can be detected in children (juvenile pernicious anemia).
  • Lymphocytic gastritis can be observed in children but is usually detected in late adulthood. On average, patients are aged 50 years.
  • Eosinophilic gastroenteritis mostly affects people younger than 50 years.
  • Patients who are symptomatic with idiopathic granulomatous gastritis usually present when they are older than 40 years.

Clinical

History

  • H pylori infection: Acute H pylori infection is usually not clinically detected, but experimental infection results in a clinical syndrome characterized by epigastric pain, fullness, nausea, vomiting, flatulence, malaise, and (sometimes) fever. The symptoms resolve in about 1 week whether or not the organism is eliminated. Persistence of the organism causes H pylori chronic gastritis, which is usually asymptomatic but may manifest as gastric pain or, rarely, with nausea, vomiting, anorexia, or significant weight loss. Symptoms may occur with the development of complications of chronic H pylori gastritis, which include peptic ulcers, gastric adenocarcinoma, and MALT lymphoma.
  • Autoimmune gastritis: The clinical manifestations are primarily related to the deficiency in cobalamin, which is not adequately absorbed because of IF deficiency as a result of severe gastric parietal cell atrophy. The disease has an insidious onset and progresses slowly. Cobalamin deficiency affects the hematologic, gastrointestinal, and neurologic systems.
    • Hematologic manifestations: The most significant manifestation is megaloblastic anemia, but, rarely, purpura due to thrombocytopenia may develop. Symptoms of anemia include weakness, light-headedness, vertigo and tinnitus, palpitations, angina, and symptoms of congestive failure.
    • Gastrointestinal manifestations: The lack of cobalamin is associated with megaloblastosis of the gastrointestinal tract epithelium. Patients sometimes report having a sore tongue. Anorexia with moderate weight loss that is occasionally associated with diarrhea may result from malabsorption associated with megaloblastic changes of the small intestinal epithelial cells.
    • Neurologic manifestations: These result from demyelination, followed by axonal degeneration and neuronal death. The affected sites include peripheral nerves, posterior and lateral columns of the spinal cord, and cerebrum. Signs and symptoms include numbness and paresthesias in the extremities, weakness, and ataxia. Sphincter disturbances may occur. Mental function disturbances vary from mild irritability to severe dementia or psychosis. The neurologic disease may occur in a patient with hematocrit and red cell parameters within the reference range.
    • Patients with pernicious anemia have an increased frequency of gastric polyps and gastric carcinoid and a 2.9-fold increase in the frequency of gastric cancer.
  • Granulomatous gastritis: In multisystemic diseases, specific symptoms related to gastric involvement may be minor. Caseating granulomas secondary to tuberculosis may be found in the absence of lung disease in patients who are malnourished, immunosuppressed, or alcoholic. Patients with Crohn disease and gastric involvement may report gastric pain, nausea, and vomiting. Gastric involvement in Crohn disease is almost invariably associated with intestinal disease, and intestinal manifestations predominate. Sarcoidosis of the stomach is usually associated with granulomatous inflammation in other locations, especially the lungs, hilar nodes, or salivary glands. About 10% of patients with sarcoid involvement in the stomach are asymptomatic. Patients who are symptomatic present with gastric ulcers, hemorrhage, pyloric stricture, and gastric outlet obstruction.
  • Idiopathic isolated granulomatous gastritis: This diagnosis is established only when known entities associated with granulomas are excluded. Patients who are symptomatic usually are older than 40 years at presentation and have epigastric pain, weight loss, and vomiting secondary to pyloric obstruction.
  • Lymphocytic gastritis: This type mostly affects middle-aged or elderly patients. Lymphocytic gastritis may be associated with chronic H pylori infection, gluten-sensitive enteropathy, and Menetrier disease. It may represent a hypersensitivity reaction involving the gastric body. Lymphocytic gastritis has been described complicating MALT lymphoma and gastric carcinoma.
  • Eosinophilic gastroenteritis: Some patients have underlying connective tissue disorders. Patients with predominant mucosal involvement may report nausea, vomiting, and abdominal pain related to the ingestion of specific foods. Patients with involvement of the muscularis propria and resulting thickening and rigidity may present with outlet obstruction symptoms. Many patients have a history of allergy, peripheral eosinophilia, asthma, eczema, or food sensitivity. Some patients have a response to removal of these items from the diet, and their condition often responds to steroid treatment.
  • Gastritis in graft versus host disease: Graft versus host disease (GVHD) follows allogeneic bone marrow transplantation or transfusions, especially in patients who are immunocompromised. Patients with isolated gastric GVHD have symptoms of nausea, vomiting, and upper abdominal pain without diarrhea.13

Physical

The physical examination is of little contributory value in chronic gastritis. However, some findings are specifically associated with the particular complications of H pylori- associated gastritis and autoimmune gastritis.

  • In uncomplicated H pylori- associated atrophic gastritis, clinical findings are few and nonspecific.
    • Epigastric tenderness may exist.
    • If gastric ulcers coexist, guaiac-positive stool may result from occult blood loss.
  • Bad breath (ie, halitosis) and abdominal pain or discomfort may occur, with bloating associated with bacterial overgrowth syndrome.
  • Physical findings may result from the development of pernicious anemia and neurologic complications in patients with autoimmune atrophic gastritis.
  • With severe cobalamin deficiency, the patient is pale and has slightly icteric skin and eyes. The pulse is rapid, and the heart may be enlarged. Auscultation usually reveals a systolic flow murmur.

Causes

See Gastroesophageal Reflux Disease. Types of chronic gastritis include the following:

  • Infectious gastritis
    • Chronic gastritis caused by H pylori infection - This is the most common cause of chronic gastritis.
    • Infection by Helicobacter heilmannii
    • Granulomatous gastritis associated with gastric infections in mycobacteriosis, syphilis, histoplasmosis, mucormycosis, South American blastomycosis, anisakiasis, or anisakidosis
    • Chronic gastritis associated with parasitic infections -Strongyloides species, schistosomiasis, Diphyllobothrium latum
    • Viral infections such as CMV and herpes virus infection14
  • Noninfectious gastritis
    • Autoimmune gastritis
    • Chemical gastropathy, usually related to chronic bile reflux or NSAID and aspirin intake
    • Uremic gastropathy
    • Chronic noninfectious granulomatous gastritis,15,16 associated with the following:
      • Crohn disease
      • Sarcoidosis
      • Wegener granulomatosis
      • Foreign bodies
      • Cocaine use
      • Isolated granulomatous gastritis
      • Chronic granulomatous disease of childhood
      • Eosinophilic granuloma
      • Allergic granulomatosis and vasculitis
      • Plasma cell granulomas
      • Rheumatoid nodules
      • Tumoral amyloidosis and granulomas associated with gastric carcinoma
      • Gastric lymphoma
      • Langerhans cell histiocytosis
    • Lymphocytic gastritis, including gastritis associated with celiac disease (also called collagenous gastritis)17
    • Eosinophilic gastritis
    • Radiation injury to the stomach
    • GVHD
    • Ischemic gastritis18
    • Gastritis secondary to drug therapy
  • Chronic gastritis of undetermined etiology or gastritis of undetermined type (eg autistic gastritis19 )

More on Gastritis, Chronic

Overview: Gastritis, Chronic
Differential Diagnoses & Workup: Gastritis, Chronic
Treatment & Medication: Gastritis, Chronic
Follow-up: Gastritis, Chronic
Multimedia: Gastritis, Chronic
References
Further Reading

References

  1. Gao L, Weck MN, Stegmaier C, Rothenbacher D, Brenner H. Alcohol consumption and chronic atrophic gastritis: Population-based study among 9,444 older adults from Germany. Int J Cancer. Jun 2 2009;[Medline].

  2. Dixon MF, Genta RM, Yardley JH, Correa P. Classification and grading of gastritis. The updated Sydney System. International Workshop on the Histopathology of Gastritis, Houston 1994. Am J Surg Pathol. Oct 1996;20(10):1161-81. [Medline].

  3. Sepulveda AR, Patil M. Practical approach to the pathologic diagnosis of gastritis. Arch Pathol Lab Med. Oct 2008;132(10):1586-93. [Medline].

  4. Weck MN, Gao L, Brenner H. Helicobacter pylori infection and chronic atrophic gastritis: associations according to severity of disease. Epidemiology. Jul 2009;20(4):569-74. [Medline].

  5. Zalewska-Ziob M, Adamek B, Strzelczyk JK, Gawron K, Jarzab B, Gubala E, et al. TNF-alpha expression in gastric mucosa of individuals infected with different virulent Helicobacter pylori strains. Med Sci Monit. Jun 2009;15(6):BR166-71. [Medline].

  6. Gao L, Weck MN, Nieters A, Brenner H. Inverse association between a pro-inflammatory genetic profile and Helicobacter pylori seropositivity among patients with chronic atrophic gastritis: Enhanced elimination of the infection during disease progression?. Eur J Cancer. May 7 2009;[Medline].

  7. Wang SY, Shen XY, Wu CY, Pan F, Shen YY, Sheng HH, et al. Analysis of whole genomic expression profiles of Helicobacter pylori related chronic atrophic gastritis with IL-1B-31CC/-511TT genotypes. J Dig Dis. May 2009;10(2):99-106. [Medline].

  8. Paniagua GL, Monroy E, Rodriguez R, Arroniz S, et al. Frequency of vacA, cagA and babA2 virulence markers in Helicobacter pylori strains isolated from Mexican patients with chronic gastritis. Ann Clin Microbiol Antimicrob. Apr 30 2009;8:14. [Medline].

  9. Redéen S, Ryberg A, Petersson F, Eriksson O, Nägga K, Borch K. Homocysteine Levels in Chronic Gastritis and Other Conditions: Relations to Incident Cardiovascular Disease and Dementia. Dig Dis Sci. Mar 7 2009;[Medline].

  10. Sheikh RA, Prindiville TP, Pecha RE, Ruebner BH. Unusual presentations of eosinophilic gastroenteritis: case series and review of literature. World J Gastroenterol. May 7 2009;15(17):2156-61. [Medline].

  11. Tanih NF, Dube C, Green E, Mkwetshana N, Clarke AM, Ndip LM, et al. An African perspective on Helicobacter pylori: prevalence of human infection, drug resistance, and alternative approaches to treatment. Ann Trop Med Parasitol. Apr 2009;103(3):189-204. [Medline].

  12. Gao L, Weck MN, Raum E, Stegmaier C, Rothenbacher D, Brenner H. Sibship size, Helicobacter pylori infection and chronic atrophic gastritis: a population-based study among 9444 older adults from Germany. Int J Epidemiol. Jul 13 2009;[Medline].

  13. Ross WA, Ghosh S, Dekovich AA, Liu S, Ayers GD, Cleary KR. Endoscopic biopsy diagnosis of acute gastrointestinal graft-versus-host disease: rectosigmoid biopsies are more sensitive than upper gastrointestinal biopsies. Am J Gastroenterol. Apr 2008;103(4):982-9. [Medline].

  14. Hasegawa Y, Goto A, Nishimura S, Sukawa Y, Fujii K, Suzuki K. Cytomegalovirus gastritis after treatment with rituximab. Endoscopy. Jul 2009;41(S 02):E199. [Medline].

  15. Shapiro JL, Goldblum JR, Petras RE. A clinicopathologic study of 42 patients with granulomatous gastritis. Is there really an "idiopathic" granulomatous gastritis?. Am J Surg Pathol. Apr 1996;20(4):462-70. [Medline].

  16. Maeng L, Lee A, Choi K, Kang CS, Kim KM. Granulomatous gastritis: a clinicopathologic analysis of 18 biopsy cases. Am J Surg Pathol. Jul 2004;28(7):941-5. [Medline].

  17. Leung ST, Chandan VS, Murray JA, Wu TT. Collagenous gastritis: histopathologic features and association with other gastrointestinal diseases. Am J Surg Pathol. May 2009;33(5):788-98. [Medline].

  18. Quentin V, Dib N, Thouveny F, L'Hoste P, Croue A, Boyer J. Chronic ischemic gastritis: case report of a difficult diagnosis and review of the literature. Endoscopy. May 2006;38(5):529-32. [Medline].

  19. Galiatsatos P, Gologan A, Lamoureux E. Autistic enterocolitis: fact or fiction?. Can J Gastroenterol. Feb 2009;23(2):95-8. [Medline].

  20. Tahara T, Shibata T, Nakamura M, Yoshioka D, Okubo M, Arisawa T, et al. Gastric mucosal pattern by using magnifying narrow-band imaging endoscopy clearly distinguishes histological and serological severity of chronic gastritis. Gastrointest Endosc. Aug 2009;70(2):246-53. [Medline].

  21. Anagnostopoulos GK, Ragunath K, Shonde A, Hawkey CJ, Yao K. Diagnosis of autoimmune gastritis by high resolution magnification endoscopy. World J Gastroenterol. Jul 28 2006;12(28):4586-7. [Medline].

  22. Capella R, C Fiocca, Cornaggia M. Autoimmune gastritis. In: Graham DY, Genta RM, Dixon MF, eds. Gastritis. Philadelphia: Lippincott Williams; 1999:79-96.

  23. Correa P. Human gastric carcinogenesis: a multistep and multifactorial process--First American Cancer Society Award Lecture on Cancer Epidemiology and Prevention. Cancer Res. Dec 15 1992;52(24):6735-40. [Medline].

  24. Dore MP, Leandro G, Realdi G, Sepulveda AR, Graham DY. Effect of pretreatment antibiotic resistance to metronidazole and clarithromycin on outcome of Helicobacter pylori therapy: a meta-analytical approach. Dig Dis Sci. Jan 2000;45(1):68-76. [Medline].

  25. Duck WM, Sobel J, Pruckler JM, Song Q, Swerdlow D, Friedman C. Antimicrobial resistance incidence and risk factors among Helicobacter pylori-infected persons, United States. Emerg Infect Dis. Jun 2004;10(6):1088-94. [Medline].

  26. Franceschi F, Genta RM, Sepulveda AR. Gastric mucosa: long-term outcome after cure of Helicobacter pylori infection. J Gastroenterol. 2002;37 Suppl 13:17-23. [Medline].

  27. Gologan A, Graham DY, Sepulveda AR. Molecular markers in Helicobacter pylori-associated gastric carcinogenesis. Clin Lab Med. Mar 2005;25(1):197-222. [Medline].

  28. Graham DY. Therapy of Helicobacter pylori: current status and issues. Gastroenterology. Feb 2000;118(2 Suppl 1):S2-8. [Medline].

  29. Graham DY, Belson G, Abudayyeh S, Osato MS, Dore MP, El-Zimaity HM. Twice daily (mid-day and evening) quadruple therapy for H. pylori infection in the United States. Dig Liver Dis. Jun 2004;36(6):384-7. [Medline].

  30. Leung WK, Kim JJ, Kim JG, Graham DY, Sepulveda AR. Microsatellite instability in gastric intestinal metaplasia in patients with and without gastric cancer. Am J Pathol. Feb 2000;156(2):537-43. [Medline].

  31. Malfertheiner P, Mégraud F, O'Morain C, Hungin AP, Jones R, Axon A. Current concepts in the management of Helicobacter pylori infection--the Maastricht 2-2000 Consensus Report. Aliment Pharmacol Ther. Feb 2002;16(2):167-80. [Medline].

  32. Rugge M, Genta RM. Staging and grading of chronic gastritis. Hum Pathol. Mar 2005;36(3):228-33. [Medline].

  33. Singhal AV, Sepulveda AR. Helicobacter heilmannii gastritis: a case study with review of literature. Am J Surg Pathol. Nov 2005;29(11):1537-9. [Medline].

  34. Sipponen P, Harkonen M, Alanko A, et al. Diagnosis of atrophic gastritis from a serum sample. Clin Lab. 2002;48(9-10):505-15. [Medline].

  35. Väänänen H, Vauhkonen M, Helske T, Kääriäinen I, Rasmussen M, Tunturi-Hihnala H. Non-endoscopic diagnosis of atrophic gastritis with a blood test. Correlation between gastric histology and serum levels of gastrin-17 and pepsinogen I: a multicentre study. Eur J Gastroenterol Hepatol. Aug 2003;15(8):885-91. [Medline].

Keywords

chronic gastritis, gastritis, Helicobacter gastritis, H pylori–associated chronic gastritis, stomach problems, stomach inflammation, type B nonatrophic gastritis, superficial nonatrophic gastritis, diffuse antral nonatrophic gastritis, chronic antral nonatrophic gastritis, interstitial-follicular nonatrophic gastritis, hypersecretory nonatrophic gastritis,

type A atrophic gastritis, diffuse corporal atrophic gastritis, pernicious anemia–associated gastritis, metaplastic atrophic gastritis, atrophic pangastritis, progressive intestinalizing pangastritis, environmental atrophic gastritis, type C reactive gastritis, bile reflux, chronic nonsteroidal anti-inflammatory drug gastropathy,

Helicobacter pylori infection, H pylori –associated multifocal atrophic gastritis, H pylori gastritis, varioliform gastritis, chemical gastritis, reactive gastritis, infectious granulomatous gastritis, gastritis in patients who are immunosuppressed, autoimmune gastritis, chronic reactive chemical gastropathy, chronic noninfectious granulomatous gastritis, lymphocytic gastritis, eosinophilic gastritis, radiation gastritis, ischemic gastritis, gastropathies,

Sydney classification of gastritis, vacuolating toxin A, VacA, CagA protein, gastric mucosa–associated lymphoid tissue lymphomas, MALT lymphomas, gastric adenocarcinomas, gastric carcinomas, gastric cancer, caseating granulomas, tuberculosis, cytomegalovirus infection, CMV infection, mycobacterial infections, anti-intrinsic factor antibodies,

pernicious anemia, NSAIDs, Crohn disease, sarcoidosis, isolated granulomatous gastritis, Eustoma rotundatum, anisakiasis, anisakidosis, hypochlorhydria, achlorhydria, hypergastrinemia, cobalamin deficiency, gluten-sensitive enteropathy,

Ménétrier disease, Helicobacter heilmannii, mycobacteriosis, syphilis, histoplasmosis, mucormycosis, South American blastomycosis, Strongyloides species, Diphyllobothrium latum, schistosomiasis, herpes virus infection, uremic gastropathy, Wegenergranulomatosis, cocaine use, plasma cell granulomas, celiac disease, Langerhans cell histiocytosis, gastric lymphoma

Contributor Information and Disclosures

Author

Sandeep Mukherjee, MB, BCh, MPH, FRCPC, Associate Professor, Department of Internal Medicine, Section of Gastroenterology and Hepatology, University of Nebraska Medical Center; Consulting Staff, Section of Gastroenterology and Hepatology, Veteran Affairs Medical Center
Sandeep Mukherjee, MB, BCh, MPH, FRCPC is a member of the following medical societies: Royal College of Physicians and Surgeons of Canada
Disclosure: Nothing to disclose.

Coauthor(s)

Antonia R Sepulveda, MD, PhD, Associate Professor of Pathology, University of Pennsylvania School of Medicine; Director of Surgical Pathology, Director of Surgical Pathology Fellowship, Department of Pathology and Laboratory Medicine, Hospital of the University of Pennsylvania
Antonia R Sepulveda, MD, PhD is a member of the following medical societies: American Association for Cancer Research, American Cancer Society, American Gastroenterological Association, American Society for Investigative Pathology, College of American Pathologists, and United States and Canadian Academy of Pathology
Disclosure: Nothing to disclose.

Maria P Dore, MD, Associate Professor, Department of Medicine, Institute of Internal Medicine, University of Sassari, Italy
Maria P Dore, MD is a member of the following medical societies: American Gastroenterological Association
Disclosure: Nothing to disclose.

Franco Bazzoli, MD, Professor, Department of Internal Medicine and Gastroenterology, University of Bologna, Italy
Franco Bazzoli, MD is a member of the following medical societies: American Gastroenterological Association
Disclosure: Nothing to disclose.

Medical Editor

Tushar Patel, MB, ChB, Professor of Medicine, Director of Hepatology, Ohio State University Medical Center
Tushar Patel, MB, ChB is a member of the following medical societies: American Association for the Study of Liver Diseases and American Gastroenterological Association
Disclosure: Nothing to disclose.

Pharmacy Editor

Francisco Talavera, PharmD, PhD, Senior Pharmacy Editor, eMedicine
Disclosure: eMedicine Salary Employment

Managing Editor

Simmy Bank, MD, Chair, Professor, Department of Internal Medicine, Division of Gastroenterology, Long Island Jewish Hospital, Albert Einstein College of Medicine
Disclosure: Nothing to disclose.

CME Editor

Alex J Mechaber, MD, FACP, Associate Dean for Undergraduate Medical Education, Associate Professor of Medicine, University of Miami Miller School of Medicine
Alex J Mechaber, MD, FACP is a member of the following medical societies: Alpha Omega Alpha, American College of Physicians-American Society of Internal Medicine, and Society of General Internal Medicine
Disclosure: Nothing to disclose.

Chief Editor

Julian Katz, MD, Clinical Professor of Medicine, Drexel University College of Medicine; Consulting Staff, Department of Medicine, Section of Gastroenterology and Hepatology, Hospital of the Medical College of Pennsylvania
Julian Katz, MD is a member of the following medical societies: American College of Gastroenterology, American College of Physicians, American Gastroenterological Association, American Geriatrics Society, American Medical Association, American Society for Gastrointestinal Endoscopy, American Society of Law Medicine and Ethics, American Trauma Society, Association of American Medical Colleges, and Physicians for Social Responsibility
Disclosure: Nothing to disclose.

 
 
HONcode

We subscribe to the
HONcode principles of the
Health On the Net Foundation

All material on this website is protected by copyright, Copyright© 1994- by Medscape.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.